327 related articles for article (PubMed ID: 20720012)
1. A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.
Zheng YL; Amin ND; Hu YF; Rudrabhatla P; Shukla V; Kanungo J; Kesavapany S; Grant P; Albers W; Pant HC
J Biol Chem; 2010 Oct; 285(44):34202-12. PubMed ID: 20720012
[TBL] [Abstract][Full Text] [Related]
2. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.
Zheng YL; Li BS; Amin ND; Albers W; Pant HC
Eur J Biochem; 2002 Sep; 269(18):4427-34. PubMed ID: 12230554
[TBL] [Abstract][Full Text] [Related]
3. AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain.
Xu M; Huang Y; Song P; Huang Y; Huang W; Zhang HT; Hu Y
J Alzheimers Dis; 2019; 70(2):573-585. PubMed ID: 31256130
[TBL] [Abstract][Full Text] [Related]
4. p10, the N-terminal domain of p35, protects against CDK5/p25-induced neurotoxicity.
Zhang L; Liu W; Szumlinski KK; Lew J
Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20041-6. PubMed ID: 23151508
[TBL] [Abstract][Full Text] [Related]
5. Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases.
Binukumar BK; Pelech SL; Sutter C; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
J Alzheimers Dis; 2016 Sep; 54(2):525-33. PubMed ID: 27567857
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.
Binukumar BK; Shukla V; Amin ND; Bhaskar M; Skuntz S; Steiner J; Winkler D; Pelech SL; Pant HC
J Alzheimers Dis; 2015; 48(4):1009-17. PubMed ID: 26444778
[TBL] [Abstract][Full Text] [Related]
7. Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation.
Kerokoski P; Suuronen T; Salminen A; Soininen H; Pirttilä T
Biochem Biophys Res Commun; 2002 Nov; 298(5):693-8. PubMed ID: 12419309
[TBL] [Abstract][Full Text] [Related]
8. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons.
Zheng YL; Kesavapany S; Gravell M; Hamilton RS; Schubert M; Amin N; Albers W; Grant P; Pant HC
EMBO J; 2005 Jan; 24(1):209-20. PubMed ID: 15592431
[TBL] [Abstract][Full Text] [Related]
9. The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.
Amin ND; Zheng Y; Bk B; Shukla V; Skuntz S; Grant P; Steiner J; Bhaskar M; Pant HC
Mol Biol Cell; 2016 Nov; 27(21):3221-3232. PubMed ID: 27630261
[TBL] [Abstract][Full Text] [Related]
10. TFP5, a peptide derived from p35, a Cdk5 neuronal activator, rescues cortical neurons from glucose toxicity.
Binukumar BK; Zheng YL; Shukla V; Amin ND; Grant P; Pant HC
J Alzheimers Dis; 2014; 39(4):899-909. PubMed ID: 24326517
[TBL] [Abstract][Full Text] [Related]
11. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
Kesavapany S; Zheng YL; Amin N; Pant HC
Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
[TBL] [Abstract][Full Text] [Related]
12. The inhibition of Cdk5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats.
Tan X; Chen Y; Li J; Li X; Miao Z; Xin N; Zhu J; Ge W; Feng Y; Xu X
Neuroscience; 2015 Apr; 290():552-60. PubMed ID: 25665755
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons.
Li G; Faibushevich A; Turunen BJ; Yoon SO; Georg G; Michaelis ML; Dobrowsky RT
J Neurochem; 2003 Jan; 84(2):347-62. PubMed ID: 12558997
[TBL] [Abstract][Full Text] [Related]
14. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.
Sun LH; Ban T; Liu CD; Chen QX; Wang X; Yan ML; Hu XL; Su XL; Bao YN; Sun LL; Zhao LJ; Pei SC; Jiang XM; Zong DK; Ai J
J Neurochem; 2015 Sep; 134(6):1139-51. PubMed ID: 26118667
[TBL] [Abstract][Full Text] [Related]
15. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
[TBL] [Abstract][Full Text] [Related]
16. Computational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore.
Cardone A; Brady M; Sriram R; Pant HC; Hassan SA
J Comput Aided Mol Des; 2016 Jun; 30(6):513-21. PubMed ID: 27387995
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation.
Corbel C; Zhang B; Le Parc A; Baratte B; Colas P; Couturier C; Kosik KS; Landrieu I; Le Tilly V; Bach S
Chem Biol; 2015 Apr; 22(4):472-482. PubMed ID: 25865311
[TBL] [Abstract][Full Text] [Related]
18. A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves neurodegenerative phenotypes.
Pao PC; Seo J; Lee A; Kritskiy O; Patnaik D; Penney J; Raju RM; Geigenmuller U; Silva MC; Lucente DE; Gusella JF; Dickerson BC; Loon A; Yu MX; Bula M; Yu M; Haggarty SJ; Tsai LH
Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2217864120. PubMed ID: 37043533
[TBL] [Abstract][Full Text] [Related]
19. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
Hisanaga S; Saito T
Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
[TBL] [Abstract][Full Text] [Related]
20. Changes in the prefrontal cortex after the hippocampus was injected with Aβ
Wang Y; Sheng H; Zhao J; Guo L; Liu J; Xu J; Liu Q; Huang J; Jiang R; Gan S; Qiu G; Lu W; Xu S; Zhu S
Neurosci Lett; 2021 Jan; 741():135453. PubMed ID: 33186609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
